Infante R, Lahita R G
Rheumatology Division, Cabrini Medical Center, New York, USA.
Geriatrics. 2000 Mar;55(3):30-2, 35-6, 39-40.
Treatment options for rheumatoid arthritis (RA) are expanding as research has provided a more complete understanding of the pathophysiology of the disease. Three disease-modifying agents approved in the last 18 months for early intervention in RA are etanercept, leflunomide, and infliximab. For the relief of the signs and symptoms of RA, the new selective cyclooxygenase-2 (COX-2) inhibitors are joining the available nonsteroidal anti-inflammatory drugs. One COX-2 inhibitor is approved for use in RA, and another is under investigation for that indication. As a class, the COX-2 inhibitors offer efficacy similar to traditional NSAIDs but with less GI and platelet toxicity.
随着研究对类风湿性关节炎（RA）的病理生理学有了更全面的认识，RA的治疗选择正在不断增加。过去18个月内批准用于RA早期干预的三种改善病情药物为依那西普、来氟米特和英夫利昔单抗。为缓解RA的体征和症状，新型选择性环氧化酶-2（COX-2）抑制剂正在加入现有的非甾体抗炎药行列。一种COX-2抑制剂已被批准用于RA，另一种正在针对该适应症进行研究。作为一类药物，COX-2抑制剂的疗效与传统非甾体抗炎药相似，但胃肠道和血小板毒性较小。
